Navigation Links
LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill
Date:12/9/2008

CINCINNATI, Dec. 9 /PRNewswire/ -- Dr. Stephen Joffe, Craig Joffe, and Alan Buckey today filed an amendment to their Schedule 13D with the U.S. Securities and Exchange Commission. The group previously filed a 13D disclosing ownership of 11.4% of LCA-Vision, Inc. (Nasdaq: LCAV), which operates 77 LasikPlus fixed-site laser vision correction centers in 33 states in the United States. Dr. Joffe is the founder and former Chairman and CEO of LCAV. Craig Joffe is the former Chief Operating Officer and General Counsel of LCAV, and Alan Buckey is the former Executive Vice President of Finance and Chief Financial Officer of the Company. The three of them worked together as the executive management team of LCAV (Nasdaq: LCAV) to grow the market capitalization of the Company well in excess of 1000% from 2003-2006.

In a letter, dated December 9, 2008, to Tony Woods and the other members of the Board of Directors of LCA-Vision, the group reiterated their "shock and disappointment" at the Board's recent decision to adopt a "stockholder rights plan," commonly known as a poison pill.

In their letter to the Board, the group states, "We are disappointed that LCA-Vision's Board did not ask shareholders to vote on the poison pill before the Board adopted it. Given the dire state of the Company, now is decidedly not the time for alleged paternalism. We believe, however, there is a solution to this recent issue. We respectfully urge the Board to call a special shareholder meeting empowering shareholders to timely vote on the poison pill. This special shareholder meeting would allow the Board of Directors and the executive management team an opportunity to more fully explain why they believe this poison pill is in fact in the best interests
'/>"/>

SOURCE Steve Joffe
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
2. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Former State Representative Terry Parke Joins Secure Services Corp.
5. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
6. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, & Countrys Top Drug Treatment CEO Barry Karlin to Keynote Palm Beach, FL National Moment Of Change Intervention Conference:
7. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
8. Former HHS Secretary Dr. Louis Sullivan, Lt. Gov. Cagle Address Need to Improve Quality of Patient Care
9. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
10. Nobel Honors 3 Former March of Dimes Prize Recipients
11. Over one-third of former American football players had sexual relations with men, study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... five times more lethal than other strains and has shown ... used to treat MRSA, according to a Henry Ford Hospital ... patients infected with the strain died within 30 days compared ... The average 30-day mortality rate for MRSA bloodstream ...
... receive a kidney transplant rarely develop the serious inflammatory ... a paper being presented at the American Society of ... Diego, CA. The findings indicate that having lupus should ... they need one. Individuals with the autoimmune disease ...
... A Henry Ford Hospital study found that hepatitis B does not ... is a contributing factor. The results contradict a previous ... previous hepatitis B infection. Hepatitis B is an inflammation of the ... presented at the American Association for the Study of Liver Diseases, ...
... ... Ontario health care professionals will hear firsthand from some of the ... in North America at an international conference on the diagnosis and treatment ... in the vitamin D field are presenting information that looks at the ...
... Amgen (Nasdaq: AMGN ) today announced the ... Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, ... kidney disease (CKD) not on dialysis, moderate anemia and ... New England Journal of Medicine and presented ...
... Oct. 30 Today Company C announced it will ... Komen for the Cure®. , On Saturday and Sunday, ... Passion for Pink event, during which 15 percent of all ... and local breast cancer awareness, research and education. A New ...
Cached Medicine News:Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:Kidney transplants generally safe for lupus patients 2Health News:Toronto Conference Targets the Vitamin D Deficiency Crisis 2Health News:Toronto Conference Targets the Vitamin D Deficiency Crisis 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 2Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 4Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 5Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 6Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 7Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 8Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 9Health News:Company C Donates $40,000 To Fight Breast Cancer 2
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... The Dimension Vista 1500 ... turbidemetry, nephelometry, IMT (integrated multisensor ... new design will integrate analysis ... chemistries, drugs-of-abuse, therapeutic drugs, immunosuppressive ...
... high performance portable ultrasound design provides ... echocardiography. Echocardiography (ultrasound) imaging requires ... and sensitive Doppler performance. The ... Terason's proprietary Teratech Architecture, delivers a ...
... passes through the GI tract, it transmits data ... the SmartPill Data Receiver, a small, light-weight, battery ... (supported by either a belt or lanyard). The ... measurement data, and elapsed and real time. After ...
... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...
Medicine Products: